Monoclonal Antibodies in Diabetes Diagnosis: Role in Type 1 (Juvenile) Diabetes
Monoclonal antibodies are not used as primary diagnostic tools for type 1 diabetes (T1D). They are research/reagent tools for measuring autoantibodies.
Actual T1D Diagnostic Criteria (ADA)
- Hyperglycemia: FPG ≥126, or 2-hr PG ≥200 on OGTT, or random PG ≥200 + symptoms, or HbA1c ≥6.5%
- Autoantibodies (confirm autoimmune etiology):
- GAD65 (glutamic acid decarboxylase) — most common (70–80%)
- IA-2 (tyrosine phosphatase) — 60–70%
- ZnT8 (zinc transporter 8) — 60–80%
- IAA (insulin autoantibodies) — higher in young children
- ICA (islet cell antibodies) — immunofluorescence, less used now
- C-peptide: Low/undetectable (confirms insulin deficiency)
- Genetic testing: HLA-DR3/DR4-DQ8 (risk stratification); monogenic diabetes genes (MODY) if atypical
How Monoclonal Antibodies Are Used
- As capture/detection antibodies in commercial autoantibody assays (ELISA, RBA, ECL)
- Research: Islet isolation, β-cell markers, immunotherapy targets (teplizumab — anti-CD3 mAb delays T1D onset)
- Not a patient-facing test — clinicians order "GAD65 antibody," not "monoclonal antibody test"
Teplizumab (Tzield)
FDA-approved (2022) anti-CD3 monoclonal antibody for delaying Stage 3 T1D in ≥8 yr olds with Stage 2 (dysglycemia + ≥2 autoantibodies). First disease-modifying therapy.
Diabetes - Related Articles
- Raw Food Diet for Diabetes: A Comprehensive Guide
- Best Blood Glucose Meters: Compare Features & Prices
- Recognizing Type 1 Diabetes in Infants: Key Symptoms and Early Signs
- Smart Carbohydrate Choices for Diabetics Seeking Weight Loss
- Diabetic Neuropathy Treatment: Current & Emerging Options
- Exercise for Insulin Resistance: Improve Blood Sugar Control
- Low Testosterone & Type 2 Diabetes: Exploring the Connection & Treatment
